Results 21 to 30 of about 5,762,549 (184)

Case report: Tenosynovial giant cell tumor [PDF]

Frontiers in Oncology
Tenosynovial giant cell tumor (TGCT) is a rare type of tumor that originates from the synovium of joints and tendon sheaths. It is characterized by recurring genetic abnormalities, often involving the CSF1 gene. Common symptoms include pain and swelling,
Anke Fähnrich, Anke Fähnrich, Zhala Gasimova, Yamil Maluje, Fabian Ott, Helen Sievert, Stephanie Fliedner, Niklas Reimer, Niklas Reimer, Axel Künstner, Axel Künstner, Niklas Gebauer, Maxim Kebenko, Nikolas von Bubnoff, Jutta Kirfel, Verena-Wilbeth Sailer, Christoph Röcken, Bjoern Konukiewitz, Wolfram Klapper, Alex Frydrychowicz, Sam Mogadas, Gerdt Huebner, Hauke Busch, Hauke Busch, Cyrus Khandanpour   +24 more
doaj   +2 more sources

Surgical treatment of spinal tenosynovial giant cell tumor: Experience from a single center and literature review [PDF]

Frontiers in Oncology, 2023
IntroductionSpinal tenosynovial giant cell tumor (TGCT) is a rare benign primary spinal tumor with aggressive behavior. The treatment strategy and prognosis of spinal TGCT remain unclear.
Shiliang Cao, Shiliang Cao, Shiliang Cao, Shiliang Cao, Liang Jiang, Liang Jiang, Liang Jiang, Shaomin Yang, Zhongjun Liu, Zhongjun Liu, Zhongjun Liu, Feng Wei, Feng Wei, Feng Wei, Xiaoguang Liu, Xiaoguang Liu, Xiaoguang Liu   +16 more
doaj   +2 more sources

Expanding the molecular spectrum of tenosynovial giant cell tumors

Frontiers in Oncology, 2022
BackgroundWhile great advances in clinical and pathological description of tenosynovial giant cell tumors (TGCT) have been made, TGCT molecular heterogeneity represents an ongoing challenge.
Thibault Gauduchon, Helene Vanacker, Helene Vanacker, Daniel Pissaloux, Philippe Cassier, Armelle Dufresne, Marie Karanian, Alexandra Meurgey, Amine Bouhamama, François Gouin, Isabelle Ray-Coquard, Isabelle Ray-Coquard, Jean-Yves Blay, Jean-Yves Blay, Franck Tirode, Mehdi Brahmi, Mehdi Brahmi   +16 more
doaj   +2 more sources

Treatment, recurrence rates and follow-up of Tenosynovial Giant Cell Tumor (TGCT) of the foot and ankle-A systematic review and meta-analysis. [PDF]

PLoS One, 2021
Background The tenosynovial giant cell tumor (TGCT) is a usually benign lesion which arises from the synovium. It affects joints, tendon sheaths and bursae. The clinical course is often unpredictable, and local recurrences frequently occur. The aim of this study was to describe different treatment options, surgical complications, and to develop a ...
Siegel M, Bode L, Südkamp N, Kühle J, Zwingmann J, Schmal H, Herget GW.   +6 more
europepmc   +6 more sources

Combined arthroscopic synovectomy and adjuvant rhenium-186 radiosynovectomy for diffuse PVNS of shoulder: a case report [PDF]

Acta Orthopaedica et Traumatologica Turcica
Diffuse tenosynovial giant cell tumor (D-TGCT), formerly known as the diffuse pigmented villonodular synovitis (PVNS) of the shoulder, is a rare condition.
Mehmet Hakan Özsoy, Sinan Yılmaz, Nuri Aslan, Mehmet Yorubulut   +3 more
doaj   +2 more sources

Pediatric patients with tenosynovial giant cell tumor: real-world evidence from an observational registry [PDF]

Orphanet Journal of Rare Diseases
Background Tenosynovial giant cell tumor (TGCT) is a rare, locally aggressive tumor originating in the synovial lining of the joint, bursa, and tendon sheath.
Sydney Stern, Patrick F. McKenzie, Giacomo G. Baldi, Thomas J. Scharschmidt, Emanuela Palmerini, Sara Rothschild   +5 more
doaj   +2 more sources

Vimseltinib for patients with tenosynovial giant cell tumor: A multicenter, open-label, phase 2 trial. [PDF]

Cancer
Abstract Background Tenosynovial giant cell tumor (TGCT) is a locally aggressive neoplasm caused by dysregulation of the colony‐stimulating factor 1 (CSF1) gene. Patients report substantial pain, stiffness, and declining physical function; those whose disease is not amenable to surgery require systemic therapy.
Stacchiotti S, Blay JY, Rutkowski P, Gelderblom H, Falcón A, Le Cesne A, Desai J, Palmerini E, Serrano C, Ganjoo KN, D'Amato GZ, Ryan CW, Wilky BA, Ferraresi V, Saleh R, Ravi V, Razak AA, Herráez AC, Ahmed M, Bernthal NM, van de Sande M, Brahmi M, Szostakowski B, Sen J, Zeringo NA, Harrow B, Narasimhan S, Saunders A, Sharma MG, Sherman ML, Wagner AJ, Tap WD.   +31 more
europepmc   +2 more sources

Diffuse-Type Tenosynovial Giant Cell Tumor of the Knee: Clinical Course After Anterior Open Synovectomy

Current Oncology
Diffuse type tenosynovial giant cell tumor (D-TGCT) of the knee presents with stiffness, pain and swelling with surgery being the mainstay treatment. However, the literature lacks data on clinical course of range of motion, pain (ROM), and swelling after
Alessandro Bruschi, Eric Staals, Andrea Sambri, Luca Cevolani, Marco Gambarotti, Alberto Righi, Michele Fiore, Eleonora Villari, Stefano Pasini, Maria Giulia Pirini, Massimiliano De Paolis, Davide Maria Donati   +11 more
doaj   +2 more sources

The Knee Tenosynovial Giant Cell Tumor: A Deceptive Case Report with Non-Specific Presentations

Journal of Orthopedic and Spine Trauma, 2023
Objective: Tenosynovial giant cell tumor (TGCT) is a rare hyperplastic condition of the joint’s synovial membrane with a high recurrence and tumor-like characteristics affecting large joints such as the hip, knee, and ankle. They often present with dull
Seyyed-Mohsen Hosseininejad, Seyyed-Morteza Kazemi   +1 more
doaj   +1 more source

Mixed-Methods to Define Meaningful Change using Exit Interviewand Clinical Trial Data in Patients with Tenosynovial Giant Cell Tumor (TGCT). [PDF]

Qual Life Res
Tenosynovial giant cell tumor (TGCT) is a locally aggressive neoplasm associated with limited range of motion (ROM), stiffness, joint damage, pain, and reduced physical functioning (PF). The MOTION Phase 3 trial (NCT05059262) was a randomized, placebo-controlled, double-blind study of vimseltinib among patients with TGCT.
Gelhorn HL, Cutts KN, Harrow B, Tait C, Saunders A, Fikre T, Han Y, Zeringo NA, Van De Sande M, Tap W, Gelderblom H, Bernthal N.   +11 more
europepmc   +4 more sources